高容量中心与早期胰腺癌新辅助化疗后胰十二指肠切除术的生存关系
该研究基于美国国家癌症数据库(2010-2016),比较早期胰腺腺癌接受新辅助治疗后行胰十二指肠切除术的患者,按机构容量分层。倾向性评分匹配后,高容量中心(≥36例/年)与更短住院时间、更低90天死亡率及更长总生存相关。
要点
- 高容量中心与更短住院时间(7 vs 8天)和更低90天死亡率(0.0% vs 5.0%)相关
- 高容量中心与更长总生存(36.3 vs 29.4个月;HR 0.73)相关
- 多数接受新辅助治疗的早期胰腺癌患者仍在低容量中心治疗
核心结论
- 高容量胰腺手术中心治疗与早期胰腺腺癌新辅助化疗后胰十二指肠切除术患者的总生存和短期术后结局改善相关。
研究设计与样本
- 基于美国国家癌症数据库(2010-2016)的回顾性队列研究,纳入临床T0-T2胰腺腺癌接受新辅助治疗后行胰十二指肠切除术的患者。
- 高容量胰腺手术中心定义为年胰切除术≥36例,采用倾向性评分1:1匹配后每组177例。
主要发现
- 匹配前低容量中心治疗1449例,高容量中心治疗250例。
- 高容量中心更多为学术/研究机构(99.4% vs 54.0%;P < .001),患者就医距离更远(65 vs 13英里;P < .001)。
- 高容量中心与更短住院时间(7 vs 8天;P = .003)和更低90天死亡率(0.0% vs 5.0%;P = .01)相关。
- 高容量中心与更长总生存相关(36.3 vs 29.4个月;P = .03;风险比0.73)。
- 在学术/研究机构的亚组分析中,高容量中心仍与更短住院时间、更低90天死亡率和更长总生存相关。
临床怎么用
- 对于早期胰腺腺癌接受新辅助化疗后拟行胰十二指肠切除术的患者,可考虑转诊至高容量胰腺手术中心以改善短期结局和生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is evidence that neoadjuvant therapy is associated with improved survival compared with upfront pancreatectomy for pancreatic adenocarcinoma. Treatment at high-volume pancreatic surgery centers is associated with improved short-term postoperative outcomes compared with low-volume centers. We compared overall survival of patients with early-stage pancreatic adenocarcinoma who received neoadjuvant therapy before resection stratified by facility volume. METHODS: Patients with clinical T0 to T2 pancreatic adenocarcinoma who received neoadjuvant therapy before pancreatoduodenectomy were identified in the National Cancer Database (2010-2016). High-volume pancreatic surgery centers performed ≥36 pancreatectomies/year. Patients were matched 1:1 by propensity score. Pathologic outcomes, postoperative outcomes, and overall survival were compared. RESULTS: Before matching, 1,449 patients were treated at low-volume centers and 250 at high-volume pancreatic surgery centers. After matching, there were 177 patients per group. High-volume pancreatic surgery centers were more commonly academic/research facilities (99.4% vs 54.0%; P < .001), and patients traveled greater distances (65 vs 13 miles; P < .001). Time from diagnosis to neoadjuvant therapy and surgery was similar. Treatment at high-volume pancreatic surgery centers was associated with shorter duration of stay (7 vs 8 days; P = .003) and lower 90-day mortality rate after pancreatoduodenectomy (0.0% vs 5.0%; P = .01). Patients treated at high-volume pancreatic surgery centers had improved overall survival (36.3 vs 29.4 months; P = .03; hazard ratio 0.73). On subset analysis of academic/research facilities, high-volume pancreatic surgery centers remained associated with shorter duration of stay, lower 90-day mortality, and greater overall survival. CONCLUSION: The majority of patients treated with neoadjuvant therapy for early-stage pancreatic adenocarcinoma received care at low-volume centers. Treatment at high-volume pancreatic surgery centers was associated with improved overall survival and short-term postoperative outcomes.
引用
- Hue JJ, Sugumar K, Markt SC, et al. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy. Surgery. 2021. PMID: 33454134. doi:10.1016/j.surg.2020.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。